In a groundbreaking leap for cardiovascular research, scientists have engineered self-assembled chamber-like cardiac organoids that faithfully mimic the complex architecture and functionality of human heart chambers. This pioneering development not only provides a transformative model for studying cardiac chamber formation but also establishes a robust platform for assessing drug-induced cardiotoxicity, potentially revolutionizing how new therapeutics are evaluated before clinical trials. Published this year in Nature Communications, the work by Zou, Wang, Zheng, and colleagues spotlights the convergence of stem cell biology, tissue engineering, and regenerative medicine, presenting an unprecedented window into the earliest steps of heart development and disease modeling.

The human heart’s intricate structure—comprising multiple chambers each with specialized functions—is notoriously challenging to replicate in vitro. Traditional two-dimensional cardiomyocyte cultures lack the spatial organization and mechanical cues necessary for proper cardiac maturation. While previous three-dimensional cardiac organoids have demonstrated contractile activity and cell heterogeneity, recreating chamber-like structures that resemble true heart morphology has remained elusive. Zou et al. surmount this hurdle by harnessing self-assembly principles, enabling pluripotent stem cells to organize autonomously into defined, chambered organoids. This architectural mimicry is essential, as the heart’s ability to pump blood relies heavily on the precise formation and interplay of distinct chambers.

Central to their approach is the optimization of culture conditions that guide stem cells down specific differentiation trajectories while promoting cellular interactions and biomechanical feedback mechanisms. Through a carefully orchestrated protocol, the research team modulated signaling pathways such as Wnt, BMP, and Notch, which are pivotal during embryonic heart development. This biochemical guidance, combined with tailored extracellular matrix components, facilitated the aggregation of cardiomyocytes, cardiac fibroblasts, and endothelial cells into a cohesive, hollow structure reminiscent of heart chambers. Notably, the organoids exhibited spontaneous contractions with coordinated electrical conduction, underscoring their functional maturity.

This model opens unprecedented avenues for interrogating the molecular and biomechanical determinants of cardiac chamber morphogenesis. Researchers can now probe how gradients of morphogens and mechanical forces sculpt chamber identity, valve formation, and myocardial patterning in a controlled laboratory environment. By recapitulating key developmental milestones in vitro, these organoids provide insight into congenital heart defects and allow for the dissection of complex gene-environment interactions that underlie cardiac malformations. The study paves the way for elucidating pathway-specific perturbations linked to heart disease.

In addition to developmental insights, the chamber-like organoids serve as a sophisticated platform for pharmacological screening. Drug-induced cardiotoxicity remains a pervasive challenge in drug development, often causing late-stage failures or post-market withdrawals. Current preclinical models, including animal testing and 2D cultures, only partially recapitulate human cardiac physiology, limiting predictive accuracy. These self-assembled cardiac organoids, by contrast, provide a human-relevant context to assess the electrophysiological, structural, and contractile effects of novel compounds, capturing subtle toxicities that conventional assays might overlook.

The research team demonstrated the utility of their platform by testing well-known cardiotoxic agents, revealing dose-dependent disruptions in organoid rhythm and contractile force. Their findings correlated with clinical manifestations observed in patients, suggesting that this model can forecast adverse cardiac responses with enhanced fidelity. This capability could streamline drug safety assessments, reduce reliance on animal models, and ultimately expedite the delivery of safer cardiovascular therapeutics to patients.

Crucially, the organoids produced by Zou et al. display remarkable reproducibility and scalability, addressing long-standing challenges in organoid research. By standardizing the self-assembly process, the team ensured consistent formation of chambers exhibiting uniform size, morphology, and cell composition across batches. This consistency lays the groundwork for larger-scale applications such as high-throughput drug screening and precision medicine initiatives, where patient-derived organoids could be tested against personalized therapeutic regimens.

Furthermore, the researchers leveraged advanced imaging and electrophysiological techniques to characterize organoid dynamics in real time. Using high-resolution confocal microscopy and multi-electrode arrays, they mapped calcium transients, electrical propagation, and mechanical contraction patterns within the chamber-like structures. These comprehensive analyses confirmed that the organoids not only structurally resemble heart chambers but also functionally emulate their synchronous beating and electrical coupling, hallmarks of a physiologically relevant cardiac model.

Beyond drug testing, the potential of these cardiac organoids extends into regenerative medicine. The ability to self-organize into chambered constructs suggests their suitability for bioengineered tissue grafts aimed at repairing damaged myocardium. Although clinical translation remains distant, the mechanistic insights gained from these models can inform strategies for enhancing cardiac regeneration, integrating stem cell therapies, and engineering next-generation heart patches.

Zou and colleagues also touched upon the ethical and logistical advantages of their organoid system. By reducing dependence on animal experimentation, their model aligns with the principles of the 3Rs (replacement, reduction, refinement) in biomedical research. Additionally, the use of human induced pluripotent stem cells enables studies on genetically diverse populations, enhancing our understanding of how individual genetic backgrounds influence heart development and drug responses.

The combination of bioengineering, developmental biology, and pharmacology embodied in this research illustrates a paradigm shift in cardiovascular science. Where once the heart was an impenetrable black box, the creation of chamber-like cardiac organoids offers a tangible window into its formation, function, and pathologies. This synthetic heart tissue platform promises to accelerate the discovery of novel treatments for heart disease, a leading cause of mortality worldwide, with profound implications for public health.

Looking forward, the research sets the stage for integrating other cell types critical to heart function, such as immune cells and specialized conduction system components, to achieve even more physiologically comprehensive organoids. Advances in microfluidics and tissue perfusion could further enhance nutrient delivery and waste removal, mimicking in vivo conditions and prolonging organoid survival. Such innovations will push the boundaries of what organoids can reveal about cardiac biology and therapeutic potential.

In summary, the self-assembled chamber-like cardiac organoids developed by Zou et al. represent an extraordinary technological and conceptual advance. By recapitulating the form and function of human cardiac chambers in vitro, they provide a powerful tool for unraveling the complexities of heart development and disease, enabling safer drug discovery, and opening new horizons for regenerative therapies. This landmark study heralds a new era in cardiovascular research where the heart’s mysteries can be explored with unprecedented clarity, precision, and relevance.

---

Subject of Research: Cardiac development, cardiac organoids, cardiotoxicity assessment, tissue engineering.

Article Title: Self-assembled chamber-like cardiac organoids for modeling cardiac chamber formation and cardiotoxicity assessment.

Article References:
Zou, X., Wang, F., Zheng, H. et al. Self-assembled chamber-like cardiac organoids for modeling cardiac chamber formation and cardiotoxicity assessment. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73822-6

Image Credits: AI Generated

In a groundbreaking development poised to revolutionize neonatal care and reproductive technologies, the emerging field of artificial womb (AW) technology has sparked intense debate among scientists, ethicists, and policymakers. As researchers publish comprehensive scoping reviews that delve into the layered ethical considerations surrounding this cutting-edge technology, it becomes evident that the future of human gestation may soon transcend traditional biological boundaries, raising profound questions about the nature of life, parenthood, and medical intervention.

Artificial wombs, also known as ectogenesis devices, are engineered life-support systems designed to mimic the biological functions of the uterus, allowing premature or otherwise vulnerable fetuses to develop in an artificial environment. Unlike conventional neonatal incubators, artificial wombs aim to recreate the complex physiological conditions that a natural womb provides, including the delivery of oxygen, nutrients, and hormonal signals essential for normal development. This technological innovation holds the potential to dramatically improve survival rates for extremely premature infants, who currently face high risks of mortality and lifelong disability.

Technical strides in AW technology have been propelled by advances in biomaterials, microfluidics, and fetal physiology. Researchers have developed sophisticated bioreactors equipped with synthetic amniotic fluid and artificial placenta interfaces capable of facilitating gas exchange and nutrient delivery while eliminating waste products. These systems simulate the mechanical and chemical environment of the womb, providing a supportive milieu that supports continuous growth and organ maturation. Animal trials have demonstrated promising results, whereby fetal lambs have been maintained inside artificial wombs for several weeks, showing notable development comparable to in utero progression.

Despite these promising advancements, the path to clinical application in humans remains fraught with technical, ethical, and regulatory challenges. One of the critical technical barriers is ensuring the precise control and replication of the uterine environment’s dynamic nature. The uterus is not a static chamber; it orchestrates complex biochemical signaling that influences the fetus’s epigenetic programming, immune system development, and neurocognitive growth. Achieving such a level of biomimicry requires integrating real-time monitoring technologies with adaptive feedback mechanisms, demanding unprecedented interdisciplinary collaboration.

The ethical dimensions introduced by artificial womb technology extend far beyond the scope of conventional neonatal care protocols. Principally, AW technology disrupts conventional understandings of gestation’s biological and social parameters. By decoupling gestation from the maternal body, it challenges the traditional gestational kinship and raises questions about the legal and moral status of the fetus under artificial care. This separation provokes debates over parental rights, responsibilities, and the potential redefinition of motherhood. Furthermore, the prospect of ectogenesis stirs societal concerns regarding reproductive autonomy, inequality, and the commodification of fetal development.

A particularly contentious aspect of artificial womb deployment pertains to the concept of viability—the gestational age at which a fetus can survive ex utero, a legal and medical benchmark for debates on abortion rights and neonatal care decisions. With AW technology potentially lowering the threshold of viability to much earlier gestational stages, this criterion could face unprecedented challenges. Ethical frameworks would need to adapt to the expanded range of survivable gestational ages, potentially reshaping public health policies and reproductive laws worldwide.

Moreover, the ramifications for fetuses with congenital abnormalities or those requiring intensive medical interventions raise critical ethical considerations. Artificial wombs could theoretically preserve and nurture fetuses previously deemed nonviable, complicating decisions about the extent of medical care and quality of life assessments. This possibility calls for robust ethical guidelines balancing the benefits of survival with respect for individual dignity and long-term outcomes.

Privacy and consent issues also loom large in this emerging field. The intimate nature of gestation, traditionally confined within the maternal body, would be externalized and subject to clinical control and technological mediation. This transition demands rigorous protocols to ensure informed consent, data privacy, and the protection of vulnerable subjects in artificial gestation settings. The question arises whether future parents or guardians can fully comprehend the implications of entrusting fetal development to machines, necessitating enhanced counseling and oversight frameworks.

Furthermore, artificial womb technology raises significant social justice concerns. Access to such advanced reproductive technologies may be limited by socioeconomic status, healthcare infrastructure, and geographic location, potentially exacerbating existing disparities in neonatal outcomes. Policymakers must therefore anticipate and address inequities in availability to prevent the widening of healthcare gaps, ensuring that AW benefits are equitably distributed.

From a psychological perspective, the impact on parent-child bonding when gestation occurs outside the maternal womb remains largely unexplored. The intimate physical and hormonal interactions during pregnancy play a pivotal role in maternal-fetal attachment and subsequent family dynamics. The absence of direct gestational involvement may influence parental bonding, emotional well-being, and child development, indicating the need for comprehensive psychological support and long-term studies.

On the regulatory front, global frameworks governing artificial womb technology are nascent and heterogeneous. Establishing consistent guidelines to oversee research, clinical trials, and eventual clinical use will require international cooperation among scientific bodies, bioethicists, and governmental agencies. Regulatory oversight must balance the encouragement of innovation with safeguarding against premature or unethical applications.

Importantly, public perception and societal acceptance will significantly influence the trajectory of artificial womb technology. Public engagement initiatives, transparency in research practices, and inclusive dialogues are essential to fostering trust and understanding. Addressing fears of “unnatural” reproduction and debunking misconceptions will be critical to integrating AW technology into mainstream medical practice sensitively.

As AW research progresses toward clinical reality, multidisciplinary collaboration will be imperative. Biomedical engineers, neonatologists, ethicists, sociologists, and lawmakers must converge to navigate the complex scientific and moral landscape. The responsible development of artificial womb technology entails anticipatory governance that proactively identifies and mitigates risks while amplifying potential benefits.

In conclusion, artificial womb technology represents a paradigm shift with monumental implications for medicine, ethics, and society. While offering hope to improve neonatal survival and reimagine reproductive possibilities, it simultaneously demands careful scrutiny of the profound ethical questions it raises. The journey from experimental prototypes to clinical tools will require deliberate, informed deliberation, ensuring that this revolutionary technology serves humanity’s best interests without compromising foundational values.

As ongoing research continues to unravel the intricacies of artificial gestation, the global community stands at a crossroads. The choices made today will sculpt the future of human reproduction and neonatal care, exemplifying the delicate interplay between scientific innovation and ethical responsibility. The promise of artificial wombs invites us to reconsider not only how life begins but also the societal frameworks that sustain it in an ever-evolving biomedical era.

---

Subject of Research:
Ethical considerations surrounding artificial womb technology and its implications for neonatal care and reproductive medicine.

Article Title:
Correction: Artificial womb technology; a scoping review of ethical considerations.

Article References:
De Bie, F.R., Paul, J., Malek, J. et al. Correction: Artificial womb technology; a scoping review of ethical considerations. J Perinatol (2026). https://doi.org/10.1038/s41372-026-02746-2

Image Credits:
AI Generated

Emerging research casting a critical eye on the widespread use of glyphosate has unveiled concerning links between exposure to this common herbicide and adverse effects on kidney function among agricultural workers in Central America. A groundbreaking cohort study conducted by a team of international scientists has meticulously measured glyphosate levels in urine samples from workers in El Salvador and Nicaragua, revealing a troubling pattern that connects chemical exposure to diminished renal health. The implications of this research extend far beyond the fields where glyphosate is applied, raising urgent questions about occupational safety, environmental health, and public policy surrounding herbicide regulation.

Glyphosate, a widely used organophosphorus herbicide found in countless agricultural products globally, has long been a subject of debate in both scientific and regulatory circles. Used extensively due to its effectiveness in controlling broadleaf weeds and grasses, glyphosate’s pervasive presence in the environment has elicited scrutiny concerning its potential toxicological effects on humans and ecosystems. The latest study approaches this discourse from a rigorous, epidemiological perspective, focusing on populations with the highest likelihood of exposure—the workers involved directly in herbicide application.

The research team undertook a robust cohort analysis, systematically collecting and analyzing urinary glyphosate concentrations from hundreds of agricultural laborers in the two Central American countries. They combined these biomonitoring efforts with comprehensive kidney function assessments, including measurement of biomarkers such as serum creatinine and estimated glomerular filtration rate (eGFR), which serve as indicators of renal performance and health. Through this integrative approach, the investigators sought to elucidate whether the burden of glyphosate accumulates in exposed individuals and if such accumulation correlates with measurable declines in kidney function.

Importantly, the study cohort was composed of workers engaged in diverse agricultural tasks, ranging from field spraying to crop maintenance, thereby encompassing a realistic spectrum of exposure gradients. The investigators incorporated detailed questionnaires addressing work practices, use of protective equipment, duration, and intensity of exposure, which allowed for nuanced statistical modeling of glyphosate’s effect on renal outcomes. This multifaceted methodology ensured that observed associations could be robustly attributed to glyphosate exposure rather than confounded by extraneous variables.

Results demonstrated a clear dose-response relationship whereby higher urinary glyphosate concentrations corresponded to diminished eGFR values, indicating early-stage kidney dysfunction. The findings are particularly alarming given that these renal impairments were detected even in the absence of overt clinical symptoms, suggesting that chronic low-level exposure may silently compromise kidney health over time. The study thus underscores the insidious nature of glyphosate toxicity which may evade detection through standard medical assessments until substantial damage has occurred.

The researchers also highlighted that many affected workers had limited access to proper protective gear or training on safe herbicide use, factors that likely exacerbated their vulnerability. The absence of rigorous occupational safeguards in many agricultural settings in developing nations amplifies the public health risk, potentially creating epidemic-like conditions of chronic kidney disease among farming communities reliant on manual labor. This evidence calls for urgent review and enhancement of worker safety protocols as a preventive measure.

Mechanistically, the study postulates that glyphosate may induce nephrotoxicity through oxidative stress pathways and disruption of renal tubular cells, as suggested by recent toxicological experiments. The herbicide’s interference with mitochondrial function in kidney cells could precipitate cellular injury, inflammation, and fibrosis, ultimately impairing the organ’s filtration capacity. Additional research is warranted to dissect these molecular pathways further, but the current epidemiological data strongly point to glyphosate as a contributing nephrotoxin.

The implications of these findings reverberate globally, considering glyphosate’s ubiquity in modern agriculture and its residues detected in various environmental compartments including water sources and food products. Populations residing near agricultural zones may be subjected to inadvertent exposure, augmenting the need for environmental monitoring and biomonitoring programs. Moreover, regulatory agencies must weigh such emerging evidence in reevaluating permissible exposure limits and enforcing stricter guidelines to protect vulnerable groups.

Public health advocates emphasize that glyphosate-related kidney dysfunction could represent a larger, underrecognized component of the global chronic kidney disease burden, particularly in tropical and subtropical regions where agricultural employment predominates. Interdisciplinary cooperation among nephrologists, toxicologists, epidemiologists, and policymakers is essential to develop targeted interventions, diagnostic strategies, and surveillance frameworks that address this growing epidemic.

Policy responses could include mandatory training for pesticide applicators, distribution of effective personal protective equipment, and the promotion of alternative weed management techniques that reduce reliance on chemical herbicides. These measures would help mitigate exposure risks while balancing agricultural productivity needs. Additionally, expanding healthcare access to early detection and management services for affected populations remains critical.

In summary, the comprehensive cohort study conducted in El Salvador and Nicaragua sheds light on the hidden health toll exacted by glyphosate exposure on kidney function among agricultural workers. The clear correlation between urinary glyphosate levels and subclinical kidney impairment not only advances scientific understanding but also challenges existing paradigms of pesticide safety. This landmark research serves as a clarion call to safeguard the wellbeing of those who labor in the fields and, by extension, the broader communities linked to agricultural production systems worldwide.

Future research trajectories should incorporate longitudinal follow-ups to track renal function trajectories over time, explore gene-environment interactions that influence susceptibility, and evaluate the efficacy of intervention strategies. Only through such concerted efforts can the full scope of glyphosate’s health impacts be comprehended and mitigated, ensuring that food production does not come at the cost of human health.

This study significantly enriches the evidence base informing ongoing debates about glyphosate regulation and underscores the urgent need for integrated policies that harmonize agricultural practices with occupational health imperatives. As glyphosate continues to be a cornerstone of weed management, embedding scientific insights into policymaking constitutes a vital step toward sustainable and just farming systems.

By addressing the silent but serious repercussions of glyphosate exposure on renal health, this research invigorates a critical discourse essential for protecting vulnerable worker populations and maintaining the integrity of public health amid evolving environmental challenges.

Subject of Research: Occupational exposure to glyphosate and its impact on kidney function in agricultural workers.

Article Title: Urine glyphosate levels and kidney function outcomes in a cohort study of workers in El Salvador and Nicaragua.

Article References:
Rodgers, K.M., Fimbres, J., Velázquez, J.J.A. et al. Urine glyphosate levels and kidney function outcomes in a cohort study of workers in El Salvador and Nicaragua. J Exp Sci Environ Epidemiol (2026). https://doi.org/10.1038/s41370-026-00913-3

Image Credits: AI Generated

DOI: 02 June 2026

A groundbreaking advancement in the imaging and surgical treatment of osteosarcoma promises to revolutionize how this aggressive bone cancer is managed, offering hope for improved outcomes through cutting-edge precision technology. At the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, researchers from Peking University Cancer Hospital and Institute in Beijing will unveil an innovative integrated PET imaging platform capable of rapidly and accurately distinguishing malignant tumor tissue from healthy tissue during surgery. This novel system not only enhances real-time decision-making in the operating room but also enables precise assessment of surgical margins, a critical factor in fully eradicating tumors and minimizing recurrence.

Osteosarcoma, the most common primary malignant bone tumor affecting children and adolescents, represents a formidable clinical challenge. The current therapeutic standard combines aggressive chemotherapy with radical surgical excision. A paramount objective for surgeons is to remove the entire tumor with clear margins, as residual tumor cells within resection boundaries markedly increase the risk of local recurrence and negatively impact patient survival. However, delineating tumor margins intraoperatively with confidence remains difficult, frequently requiring surgeons to make empirical decisions based on visual and tactile feedback—methods insufficient for microscopic precision.

This clinical necessity spurred the development of a sophisticated multi-modal imaging platform engineered to overcome existing limitations. Central to the technology is the targeting of B7-H3, a transmembrane protein highly expressed in over 80% of osteosarcoma tumors. Recognizing this protein’s selective overexpression, researchers successfully synthesized a novel radiotracer, designated ^68Ga-B7H3-BCH, that selectively binds to B7-H3 molecules, enabling highly specific and sensitive detection of osteosarcoma lesions through PET imaging.

Preclinical assessments underscored the superior diagnostic capability of the ^68Ga-B7H3-BCH tracer, demonstrating marked improvements in lesion detection and tumor delineation compared to conventional radiotracers like ^18F-FDG. Encouraged by these findings, the research team architected an integrated imaging pipeline that synergizes ^68Ga-B7H3-BCH PET/CT scanning with a near-infrared (NIR) B7H3 fluorescent probe. This dual-modality approach facilitates comprehensive preoperative tumor staging and equips surgeons with real-time fluorescence visualization during tumor resection procedures.

During the surgical phase, the NIR fluorescent probe illuminates tumor borders with high spatial and temporal resolution, guiding surgeons to excise malignant tissues precisely while preserving as much healthy bone and surrounding structures as possible, which is vital for maintaining limb functionality. Following tumor removal, the platform incorporates a rapid pathological margin verification technique capable of providing conclusive margin status within 30 minutes, dramatically expediting what traditionally is a protracted pathological process and enhancing surgical confidence.

Mouse model studies exhibited robust uptake of the ^68Ga-B7H3-BCH tracer within osteosarcoma lesions and at tumor margins, correlating well with histopathological analysis and validating the tracer’s specificity. The combination of non-invasive, whole-body PET/CT imaging for systemic staging and intraoperative fluorescence for margin delineation embodies a truly personalized, closed-loop diagnostic and therapeutic strategy.

The implications of this integrated platform extend beyond mere imaging enhancements. It introduces a paradigm shift toward precision oncology in osteosarcoma, transitioning from empirical surgery followed by standard systemic chemotherapy to individualized treatment plans shaped by precise molecular and anatomical tumor information. Such tailoring is poised not only to improve local control rates but also to reduce unnecessary removal of healthy tissue, ultimately translating into better functional outcomes and quality of life for patients.

Bo Mei, PhD, the principal investigator spearheading this innovation, emphasized the urgent clinical need: “Orthopedic surgeons need a reliable, rapid method to accurately delineate tumor margins in real-time during osteosarcoma surgeries. Our integrated platform meets this challenge, redefining surgical oncology practices by incorporating molecular targeting and advanced imaging modalities.”

Although still at the investigational stage, early human feasibility studies employing the ^68Ga-B7H3-BCH platform have shown promising results. These pilot data demonstrate the platform’s potential to function effectively in clinical settings, marking a critical step toward regulatory approval and widespread adoption. Future efforts will focus on comprehensive prospective clinical trials to robustly establish safety, efficacy, and workflow integration within orthopedic oncology centers.

The technical innovation rests heavily on multimodal probe development, marrying the quantitative power of PET imaging with the exquisite real-time spatial resolution of fluorescence imaging. This combination overcomes intrinsic limitations of each modality when used in isolation—PET provides metabolic and molecular insights but is limited in spatial resolution and intraoperative applicability, while fluorescence enables visual guidance but lacks systemic diagnostic capability.

The platform’s rapid intraoperative margin assessment, with results available in less than half an hour, is a significant advance that replaces delayed histopathology consultation, allowing surgeons to adjust the extent of resection dynamically and immediately. By integrating molecular targeting, imaging, and pathology, this closed-loop diagnostic and therapeutic construct exemplifies next-generation precision medicine and theranostics.

This innovation also represents a promising template for other solid tumors exhibiting targetable biomarkers, suggesting broad applicability across oncology. The integration of molecularly specific PET tracers with intraoperative fluorescence guidance and rapid pathology verification embodies a comprehensive approach that can be adapted and refined for diverse malignancies beyond osteosarcoma.

As SNMMI 2026 unfolds, this pioneering work will undoubtedly attract attention from the nuclear medicine, surgical oncology, and molecular imaging communities. The researchers’ abstract, detailing the development and validation of the ^68Ga-B7H3-BCH PET/fluorescence multimodal probe and integrated imaging platform, underscores the convergence of technology and translational science, poised to enhance patient care profoundly.

This new frontier in osteosarcoma management showcases how targeted molecular imaging coupled with innovative surgical navigation can dramatically improve diagnostic accuracy, surgical precision, and ultimately patient prognosis. It exemplifies the power of integrating molecular biology, chemistry, imaging technology, and clinical expertise into a cohesive solution designed to address one of the most challenging pediatric cancers.

Subject of Research: Osteosarcoma, molecular imaging, surgical margin assessment, precision oncology
Article Title: An Integrated PET Imaging Platform for Real-Time Surgical Guidance and Accurate Margin Assessment in Osteosarcoma
News Publication Date: 2026 (presented at SNMMI Annual Meeting)
Web References: SNMMI 2026 Annual Meeting Abstract
Image Credits: Courtesy of SNMMI
Keywords: Osteosarcoma, B7-H3, PET Imaging, Molecular Imaging, Near-Infrared Fluorescence, Surgical Navigation, Radiotracer, Precision Medicine, Tumor Margin, Theranostics

In an unprecedented exploration into the dynamic interplay between microbiota and host physiology, a groundbreaking study has illuminated the pivotal role of microbial enzymes in modulating gut motility through reactivation of host androgens. Published in Nature Neuroscience in 2026, this research uncovers how microbial metabolism intricately directs enteric neuronal circuits, reshaping our understanding of the gut-brain axis with profound implications for human health and disease.

The study embarks from the well-documented influence of androgens—steroid hormones traditionally associated with male traits—on various physiological systems. While systemic androgen effects have been explored, this investigation probes deeper into localized reactivation mechanisms within the gut environment, where microbial communities reside densely. Researchers reveal that resident gut microbes possess enzymatic functions capable of converting androgen precursors back into their active forms, effectively reawakening hormonal signaling within the enteric nervous system.

Employing a sophisticated combination of metabolomic profiling, genetic manipulation, and electrophysiological techniques, the team identified key bacterial taxa responsible for this enzymatic reactivation. Notably, these microbial metabolic activities were found to significantly enhance the bioavailability of active androgens in the gut lumen, directly influencing neuronal excitability and, consequently, gut motility patterns. This discovery bridges a vital gap between microbiome functionality and neuroendocrine regulation that had remained elusive until now.

Central to the findings is the concept that androgen reactivation by microbial enzymes fine-tunes enteric neuronal output, orchestrating peristaltic reflexes and smooth muscle contractions essential for intestinal transit. Through targeted in vivo experiments, the researchers demonstrated that disruption of this microbial androgen metabolism altered gut motility, resulting in either hypo- or hypermotility phenotypes. These effects were reversible upon restoration of the microbial enzymatic activity, suggesting a highly dynamic and plastic system governed by host-microbiome feedback loops.

Beyond the immediate mechanistic insights, this study challenges conventional paradigms by positioning gut microbes as active endocrine modulators rather than passive inhabitants. The realization that microbial metabolism can recalibrate host hormonal circuits highlights novel avenues for therapeutic intervention in gastrointestinal disorders characterized by dysmotility, such as irritable bowel syndrome and chronic constipation. Modulating microbial androgen reactivation could become a precision medicine strategy tailored to restore normal gut function.

Intriguingly, the researchers also unveiled sexually dimorphic responses in the interplay between microbial androgen reactivation and enteric neuron function. Male and female mice exhibited distinct motility patterns contingent upon variations in microbial enzymatic profiles and host androgen sensitivity, underscoring the importance of considering sex as a biological variable in gut-neuroendocrine research. This facet deepens our appreciation of individualized host-microbe interactions shaping health outcomes.

At the molecular level, the study elaborates on how microbial enzymes such as hydroxysteroid dehydrogenases catalyze reversible conversions between inactive androgen conjugates and their active counterparts. These enzymatic reactions take place in close proximity to enteric neurons, facilitating paracrine signaling that modulates neuronal firing rates and neurotransmitter release. This finely tuned mechanism enables the microbiome to exert sophisticated control over gut motility beyond mere metabolite production.

Furthermore, the research integrates advanced imaging modalities to visualize neuronal activity in real-time, correlating enhanced androgen availability with increased calcium fluxes and action potential frequency within enteric ganglia. This real-time functional evidence solidifies the link between microbial metabolic activity and neurophysiological outputs, offering a multi-dimensional perspective of gut regulatory networks. The convergence of metabolic and neuronal data lends robust credibility to the proposed model.

From an evolutionary standpoint, the elucidation of microbial androgen reactivation mechanisms hints at a co-evolved symbiotic relationship where microbes contribute to optimizing host intestinal function. This evolutionary insight expands the framework of mutualism, suggesting that microbiota-derived modulation of hormone signaling constitutes an adaptive advantage for maintaining digestive efficiency. Such findings provide fertile ground for evolutionary biology and microbiome research intersections.

The translational potential of these discoveries is immense. By identifying specific microbial enzyme targets, pharmaceutical development can aim to design modulators or probiotics that enhance or inhibit androgen reactivation within the gut, thereby controlling motility disorders. Moreover, these microbial pathways might influence systemic endocrine functions given the interconnectivity between enteric neurons and central nervous system circuits, opening exciting possibilities for neurogastroenterology.

Intricately, the study also discusses the feedback mechanisms wherein host androgens modulate microbial community composition and metabolic activity, establishing a bidirectional communication loop. This dynamic feedback ensures homeostasis by synchronizing microbial function with host hormonal status, representing an elegant biological system integrating metabolic, neuronal, and microbial domains. Such complexity underscores the need for holistic approaches in future gut-brain axis investigations.

Given the widespread prevalence of gut motility disorders, the identification of microbial androgen reactivation as a key regulatory mechanism invites renewed scrutiny of microbiome-targeted therapies. Dietary interventions, antibiotics, and microbiota transplants could inadvertently perturb these enzymatic activities, altering gut function. Therefore, medical practices may need to incorporate microbiome endocrine considerations to optimize patient outcomes and minimize adverse effects.

In conclusion, this seminal study redefines the microbial contribution to host physiology by unveiling a novel enzymatic process through which gut bacteria reactivate androgens, orchestrating enteric neuronal regulation of motility. This intricate biochemical crosstalk exemplifies the emerging frontier of microbiome-endocrine interactions with vast implications for biology, medicine, and therapeutics. As we unravel these complex dialogues, the prospect of leveraging microbial endocrinology to modulate health becomes an exciting reality.

The transformative insights gained here invite a paradigm shift: the gut microbiome is not merely a metabolic organ but an endocrine entity capable of recalibrating host neurophysiological processes. This revelation paves the way for integrative research endeavors bridging microbiology, endocrinology, neuroscience, and clinical medicine, ultimately advancing personalized healthcare in gastrointestinal and systemic diseases. Such interdisciplinary synergy heralds a new epoch of microbiome-informed biomedical breakthroughs.

As the field advances, further studies will doubtless explore how microbial androgen reactivation interfaces with other hormonal axes and systemic immunity, deepening our comprehension of host-microbiome symbiosis. The interplay between microbial enzymatic activities and host signaling cascades likely extends beyond gut motility, influencing metabolism, mood, and behavior. The future of human health hinges upon decoding these microbial endocrine networks and harnessing their potential.

---

Subject of Research: Microbial enzymatic reactivation of host androgens and their role in enteric neuronal regulation of gut motility.

Article Title: Microbial reactivation of host androgens directs enteric neuronal regulation of gut motility.

Article References:
Lagomarsino, V.N., Robinson, A., Mitchell, P.E. et al. Microbial reactivation of host androgens directs enteric neuronal regulation of gut motility. Nat Neurosci (2026). https://doi.org/10.1038/s41593-026-02321-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41593-026-02321-0

A research collaboration has developed a novel fluorescent nanosensor capable of rapidly detecting indole-3-propionic acid (IPA), an emerging biomarker linked to gut health and disease. The breakthrough is described in the team's paper, "Fluorescent Nanosensor for Indole-3-Propionic Acid Detection in Gut Health Monitoring," published in the journal Advanced Healthcare Materials.

In the rapidly evolving arena of synthetic biology, precise gene regulation remains both a crucial goal and formidable challenge. Bacteria, with their intricate genetic networks and vital roles in biotechnology, serve as prime targets for engineering sophisticated gene control systems. Now, a groundbreaking study published in Nature Biotechnology unveils an innovative strategy harnessing an attenuated form of Cas13d—a powerful RNA-targeting CRISPR effector—to achieve programmable, multiplexed, and orthogonal gene regulation in Escherichia coli. This advancement opens unprecedented avenues for dynamic bacterial gene control, enabling nuanced modulation of gene expression with high specificity and minimal cytotoxicity.

Traditional CRISPR systems like Cas9 have revolutionized DNA editing, yet RNA-targeting effectors such as Cas13 bring unique advantages for reversible and tunable regulation without permanent genomic alterations. However, the application of Cas13 in bacteria has encountered a significant barrier: collateral cleavage activity. Wild-type Cas13 exhibits nonspecific RNA degradation once activated, leading to cytotoxicity and growth inhibition, thus impeding its widespread use for precise transcriptional tuning in prokaryotic cells. Overcoming this limitation required a reimagination of the Cas13 protein architecture.

The researchers addressed this by adopting a rational protein engineering approach, focusing on attenuating Cas13d’s RNase activity while preserving its targeted RNA knockdown capacity. They identified and excised flexible regions within the Cas13d protein structure hypothesized to contribute to unwanted collateral cleavage. This targeted truncation yielded a spectrum of Cas13d variants with tunable enzymatic activity. Notably, these engineered Cas13d proteins maintained their ability to silence specific transcripts efficiently, yet exhibited drastically reduced cytotoxicity, as evidenced by a remarkable 2.2-fold increase in bacterial growth optical density compared to cells harboring wild-type Cas13d.

Beyond simply dampening RNase activity, this attenuated Cas13d toolkit demonstrated an exquisite level of functional versatility, modulated by subtle changes in CRISPR RNA spacer design. By introducing proximal mismatches at the 5′ end of the spacer sequences, the system enables a programmable switch among three distinct modes of gene regulation: translation inhibition, targeted degradation of polycistronic mRNAs, and CRISPR activation at the translation level via fusion to the bacterial initiation factor IF3. This modularity allows tailored control strategies for diverse applications, ranging from silencing deleterious genes to upregulating beneficial pathways.

A particularly compelling aspect of this work is the system’s capability to exert multiplexed and orthogonal regulation within polycistronic transcripts—bacterial mRNAs that encode multiple proteins in a single RNA molecule. By designing guide RNAs targeting specific genes within these operons, the researchers successfully demonstrated simultaneous and independent control of individual gene expression. This level of granularity in bacterial gene editing was previously unattainable with conventional CRISPR tools and holds immense potential for engineering complex synthetic circuits with multiple inputs and outputs.

To showcase the practical utility of this attenuated Cas13d system, the team applied it to a classic microbial biotechnology challenge: optimization of lycopene biosynthesis in E. coli. Lycopene, a valuable carotenoid with health and industrial relevance, is synthesized via a multi-enzyme metabolic pathway that requires careful balancing of enzyme levels and fluxes. Employing their refined Cas13d-based regulatory toolkit, the researchers fine-tuned essential and competing genes within this pathway dynamically. The resulting pathway rewiring not only enhanced lycopene yields significantly but also maintained cell vitality, illustrating the harmony between metabolic optimization and cell health achievable with this sophisticated regulatory platform.

The implications of this advance ripple well beyond E. coli or lycopene synthesis. The modular, tunable nature of attenuated Cas13d effectors paves the way for next-generation microbial synthetic biology applications—from bioproduction of complex molecules to living biosensors that respond rapidly to environmental cues. The reversible and multiplexed control mechanism offers a potent toolset for probing fundamental bacterial gene function and constructing synthetic circuits with unprecedented precision.

Moreover, this technology elegantly sidesteps the permanent genomic disruptions characteristic of DNA-targeting CRISPR tools. By targeting RNA transcripts post-transcriptionally, this approach enables reversible modulation of gene expression states, allowing researchers to study temporal dynamics in bacterial physiology or develop programmable microbes that can switch functionalities in response to stimuli.

The engineering of Cas13d itself involved exploiting detailed structural and functional knowledge. Flexible regions previously overlooked were pinpointed as critical determinants for collateral cleavage. This insight underscores the power of combining structural biology with synthetic biology to reimagine natural effectors as finely controllable tools rather than blunt instruments. It opens the door for similar attenuation strategies to be applied to other RNA-targeting nucleases, amplifying the toolkit available for RNA biology and biotechnology.

The use of proximal spacer mismatches to toggle between inhibition, degradation, and activation states represents a clever exploitation of CRISPR RNA–target complementarity rules. This innovation decouples RNase activity from binding affinity and allows a single engineered Cas13d protein to perform multiple regulatory roles without further protein engineering, streamlining system design and increasing flexibility.

Importantly, the orthogonal targeting within polycistronic mRNAs highlights the potential for sophisticated bacteria-wide gene regulation at the RNA level. Since many bacterial operons encode functionally linked proteins, this ability to recalibrate individual gene outputs independently provides a powerful lever to dissect and rewire bacterial gene networks with minimal disturbance to overall cellular integrity.

The improved growth performance of bacteria expressing attenuated Cas13d variants is a vital advancement for biotechnological deployment. The reduced toxicity facilitates higher cell densities and longer cultivation times, improving production scalability. This contrasts sharply with previous Cas13 systems, where collateral damage to cellular RNAs often stagnated growth and limited practical utility.

From therapeutic applications aiming to modulate microbial communities to industrial biosynthesis frameworks requiring dynamic metabolic flux control, the attenuated Cas13d toolkit stands as a versatile and impactful innovation. It bridges longstanding gaps in RNA-targeting technologies, balancing potency with biocompatibility and programmability.

In conclusion, this study represents a seminal step in realizing dynamic, multiplexed, and reversible gene control in bacteria through rational engineering of Cas13d. By attenuating collateral cleavage and introducing spacer design-based functional switching, the authors have delivered a powerful RNA regulatory toolkit poised to transform microbial synthetic biology and biotechnology. Future research will undoubtedly explore expanding this system to diverse bacterial species, integrating it with other synthetic genetic elements, and harnessing its potential for real-time cellular reprogramming.

The scientific community is certain to embrace this versatile platform, which not only enhances our capacity to engineer bacteria but also deepens our understanding of RNA biology and CRISPR functionality. As synthetic biology marches forward, such innovations redefine the frontier of microbial gene control, unlocking new possibilities from medicine to sustainable biomanufacturing.

---

Subject of Research:
Programmable, multiplexed, orthogonal gene control in bacteria using engineered, attenuated Cas13d systems.

Article Title:
Programmable, multiplexed and orthogonal gene control in bacteria with attenuated Cas13d systems.

Article References:
Tong, S., Qin, Y., Sun, Y. et al. Programmable, multiplexed and orthogonal gene control in bacteria with attenuated Cas13d systems. Nat Biotechnol (2026). https://doi.org/10.1038/s41587-026-03160-x

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41587-026-03160-x

In a groundbreaking study poised to reshape the landscape of cancer therapeutics, researchers have unveiled a novel resistance mechanism in colorectal cancer that challenges the efficacy of KRAS inhibitor treatments. Published in Nature Communications in 2026, the research led by Guo, Zhong, Hu, and their colleagues uncovers how colorectal tumors can circumvent the cytotoxic effects of KRAS pathway inhibition by dynamically rewiring the mevalonate pathway through enhancer remodeling. This discovery shines a light on the intricate molecular circuitry cancer cells exploit to sustain their malignancy and reveals a new frontier for therapeutic intervention.

KRAS mutations, long recognized as critical drivers in various cancers, have been notoriously difficult to target effectively. Recent advances in small molecule inhibitors have enabled direct targeting of mutant KRAS proteins, offering new hope particularly for colorectal cancer patients harboring these mutations. However, clinical trials revealed an emerging pattern of resistance, with tumors rapidly adapting and resuming growth despite continuous KRAS inhibition. The study’s authors set out to decipher the molecular underpinnings that empower tumors to resist these once-promising agents.

At the core of their discovery lies the mevalonate pathway, a critical metabolic cascade responsible for producing sterols, isoprenoids, and other essential biomolecules involved in cell membrane integrity, protein prenylation, and cell signaling. Intriguingly, the research demonstrates that colorectal cancer cells, when faced with blockade of KRAS signaling, undergo profound enhancer remodeling — epigenetic and chromatin-based changes that rewire gene regulatory elements — which in turn upregulates components of the mevalonate pathway. This adaptive metabolic shift not only compensates for the inhibited KRAS activity but also fuels continued tumor cell survival and proliferation.

Utilizing state-of-the-art epigenomic profiling techniques, including ATAC-seq and ChIP-seq, the investigators mapped dynamic changes in enhancer landscapes in colorectal tumors subjected to KRAS inhibitor treatment. Their data reveal a robust activation of enhancers associated with key mevalonate pathway genes, correlating with increased transcriptional output. These enhancer regions exhibit hallmark features of activation, such as heightened H3K27ac marks, underscoring the tumor’s epigenetic plasticity as a driving force behind therapeutic resistance.

The functional consequences of mevalonate pathway enrichment were explored through comprehensive metabolomic and lipidomic analyses. Cancer cells demonstrated elevated levels of cholesterol, farnesyl pyrophosphate, and geranylgeranyl pyrophosphate—metabolites critical for post-translational modification of signaling proteins, including small GTPases beyond KRAS itself. This suggests that the tumor’s metabolic flexibility allows bypassing of blocked KRAS signaling by fostering alternative prenylation-dependent oncogenic pathways, sustaining malignant phenotypes.

Crucially, pharmacological inhibition of enzymes within the mevalonate pathway, such as HMG-CoA reductase, in combination with KRAS inhibitors, reversed resistance and significantly impaired tumor growth in preclinical colorectal cancer models. These findings pave the way for novel combinatorial therapeutic strategies that target both signaling and metabolic axes, potentially transforming current clinical management of KRAS-mutant colorectal cancer.

The implications of enhancer remodeling driven metabolic rewiring extend beyond colorectal cancer. Given the prevalence of KRAS mutations across multiple tumor types, similar adaptive resistance mechanisms may underlie therapeutic failure in lung and pancreatic cancers treated with KRAS inhibitors. This highlights the imperative to integrate epigenomic and metabolic profiling in future clinical trials to identify biomarkers predictive of resistance and optimize treatment regimens.

At a molecular level, enhancer remodeling involves recruitment and redistribution of transcription factors and coactivators, altering chromatin accessibility landscapes. The study identifies key players such as BRD4 and the histone acetyltransferase p300 as facilitators of enhancer activation at mevalonate pathway loci. Targeting these epigenetic modulators with BET inhibitors or HAT inhibitors demonstrated partial restoration of KRAS inhibitor sensitivity, providing additional therapeutic avenues.

This research underscores the complexity of cancer resistance, reinforcing the concept that tumor cells can co-opt fundamental biological processes—such as epigenetic regulation and metabolic flux—to evade targeted therapies. It exemplifies the necessity of multidimensional therapeutic interventions that concurrently address both genetic drivers and adaptive cellular states.

Moreover, the study emphasizes the evolving role of advanced genomic and epigenomic technologies in oncology research. The integration of enhancer landscape mapping with metabolic profiling creates a powerful framework for uncovering hidden resistance pathways. This systems biology approach will be crucial to staying one step ahead of cancer evolution and therapeutic evasion.

In conclusion, the elucidation of mevalonate pathway rewiring driven by enhancer remodeling as a mechanism conferring resistance to KRAS inhibitors represents a major leap in our understanding of colorectal cancer biology. It advocates for the development of combination therapies that strategically target interconnected oncogenic networks. Future clinical trials incorporating inhibitors of both the KRAS signaling axis and mevalonate metabolism hold promise for overcoming resistance and improving patient outcomes.

As the war against cancer advances into new terrain, studies like this reveal the adaptive ingenuity of tumor cells and the sophisticated molecular arms race that defines modern oncology. By illuminating these concealed survival tactics, researchers provide both a warning and a beacon—resistance is inevitable, but so too is the potential for innovative solutions grounded in deep mechanistic insight.

The road ahead demands close collaboration between basic scientists, clinicians, and pharmaceutical developers to translate these insights into effective therapies. Precision oncology is entering an era where epigenetic and metabolic plasticity are recognized as central determinants of therapeutic success. Understanding and targeting these dynamic cellular programs will be key to achieving durable remissions in KRAS-mutant colorectal cancer and beyond.

---

Subject of Research: Resistance mechanisms in colorectal cancer involving mevalonate pathway rewiring and enhancer remodeling under KRAS inhibitor treatment.

Article Title: Mevalonate pathway rewiring driven by enhancer remodelling confers resistance to KRAS inhibitors in colorectal cancer.

Article References:
Guo, Y., Zhong, Y., Hu, P. et al. Mevalonate pathway rewiring driven by enhancer remodelling confers resistance to KRAS inhibitors in colorectal cancer. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73805-7

Image Credits: AI Generated

A long-awaited study of people with ME/CFS revealed differences in their immune and nervous system. The findings may offer clues about long COVID

© Jorm Sangsorn/Getty Images

Researchers from the University of Cambridge have created a new DNA sequencing method called Chem-map, which can detect where and how small molecule drugs interact with the targeted genome. The method enables researchers to conduct in situ mapping of small molecule-genome interactions with unprecedented precision. Chem-map was used in the study to determine the direct […]

The post DNA sequencing method lifts ‘veil’ from genome black box appeared first on Science Bulletin.

Dentists, as well as periodontists, use several handheld oral surgical instruments. One such commonly used instrument includes dental chisels. This instrument has a unique design for splitting the tooth when it has any fracture. Likewise, the instrument consists of a beveled cutting edge on either side to assist the dentist while doing a complicated surgery. […]

The post What Are The Purposes Of Using Dental Chisels In Oral Surgical Procedures? appeared first on Science Bulletin.

A large phase 3 clinical trial has revealed promising results for a once-nightly pill designed to treat obstructive sleep apnea by targeting the biological mechanisms that cause airway collapse during sleep. A once-nightly pill significantly improved obstructive sleep apnea (OSA) symptoms in a large phase 3 clinical trial presented at the 2026 ATS International Conference. [...]

Spinal cord injuries can have devastating consequences for those affected. Nerve cells in the spinal cord rarely regenerate naturally, while scarring often prevents the regrowth of nerve fibers. Modern therapies attempt to influence implanted stem cells using electrical stimulation to promote the growth of new nerve cells. This approach has several drawbacks: it requires implanted electrodes, and the transplanted cells do not always survive or integrate properly into the existing tissue.

Lung cancer remains one of the world's deadliest cancers, yet despite decades of effort to develop new drugs, many fail because they don't stay in the body long enough to be effective or because they damage healthy organs. Now, Adelaide University researchers have developed a novel nanoparticle "delivery vehicle" that precisely targets cancer drugs to the lungs while helping to limit harmful side effects—a breakthrough that could reshape how the disease is treated.

Scientists at ETH Zurich have developed an ultra-thin silicon material that can guide vibrations along carefully designed paths, much like roads directing traffic. The breakthrough could lead to new technologies for energy harvesting, advanced sensors, and even future computers that work without electricity. The new material belongs to a class known as metamaterials. While metamaterials […]

The post New silicon material could guide vibrations like traffic on a highway appeared first on Knowridge Science Report.

For many older adults, major surgery can bring important benefits. Procedures such as hip replacements can reduce pain and improve mobility, while abdominal surgeries can treat serious medical conditions and improve quality of life. However, a growing body of research suggests that surgery may affect more than just the body. It may also have lasting […]

The post Major Surgery May Speed Up Memory Decline in Older People appeared first on Knowridge Science Report.

When people cannot sleep well, they often look for quick solutions. Sleep medications are commonly prescribed, and one drug that has gained popularity in recent years is quetiapine. Although the medication was originally approved for schizophrenia and bipolar disorder, many doctors prescribe it in low doses to help patients with insomnia because of its strong […]

The post Common Sleep Pill May Create Hidden Risks for People with Sleep Problems appeared first on Knowridge Science Report.

A new study offers encouraging news for people who have been treated for melanoma, the most dangerous form of skin cancer. Researchers have found that combining a personalized mRNA vaccine with an existing cancer immunotherapy drug may significantly reduce the chances of the disease returning after surgery. The research was led by scientists at NYU […]

The post This Cancer Vaccine Cuts Skin Cancer Recurrence Nearly in Half appeared first on Knowridge Science Report.

Muscle loss is a serious but often overlooked problem in people with advanced liver disease. Many patients with end-stage liver disease gradually lose muscle mass and strength, making it harder to carry out daily activities, maintain independence, and recover from illness. This condition, known as sarcopenia, affects about one in three people with severe liver […]

The post Different Liver Diseases Cause Different Types of Muscle Loss appeared first on Knowridge Science Report.

Why do our brains become more vulnerable to memory loss and disease as we get older? This question has challenged scientists for decades. While researchers have identified many changes that occur in aging brains, finding the underlying cause has been much more difficult. A new study from Stanford University may bring scientists one step closer […]

The post Stanford Scientists Find a Possible Root Cause of Brain Aging appeared first on Knowridge Science Report.